Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Durbin Plc
Durbin Plc
Activities:
Distribution
Regulatory
Logistics
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Distribution
Durbin and Jazz coordinate early access for wakefulness medicine
Jazz will partner with Durbin to make Sunosi available to patients meeting defined criteria
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Supplying the one in a million
How has the onset of orphan drugs affected the supply chain?
Regulatory
Medical Need Europe appoints Durbin as latest distribution partner
Initially the agreement will involve a single product, which is currently under clinical development for the management of progressive multiple sclerosis
Subscribe now